HK Stock Market Move | CSTONE PHARMA-B(02616) rose more than 3% and will announce Phase I dose escalation clinical data of PD-1/VEGF/CTLA-4 triple antibodies at the ESMO conference.

CSTONE PHARMA-B(02616) rose more than 3%, as of the time of publication, up 2.79% to HK$6.99, with a trading volume of HK$15.3838 million. In terms of news, CSTONE PHARMA-B announced that the 2025 European Society for Medical Oncology (ESMO) Annual Meeting will be held in Berlin, Germany from October 17 to 21, 2025. The core clinical pipeline of CStone Pharma, CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) ongoing Phase I dose-escalation clinical data summary and CS5001 (ROR1 antibody-drug conjugate [ADC]) ongoing Phase Ib clinical study design summary have been published on the ESMO official website. The summary of CS2009 only covers the baseline data of 9 patients as of May 8, 2025 (the summary submission deadline), aiming to meet the abstract submission requirements of ESMO. At the upcoming ESMO Congress, CStone Pharma will present preliminary data from the Phase I dose-escalation clinical study of CS2009 in approximately 70 patients with advanced solid tumors in poster form, making it the first clinical data presentation globally on the PD-1/VEGF/CTLA-4 trispecific antibody.